AstraZeneca Pharma India Limited has announced the appointment of Mrs. Sandhya Tejaswini Amanna as Director - Legal, effective March 18, 2026. The appointment was approved by the Board of Directors based on the recommendation of the Nomination and Remuneration Committee, as disclosed under Regulation 30 of SEBI Listing Regulations.

Appointment Details

The company has classified this as a Senior Management Personnel position under SEBI Listing Regulations. Mrs. Amanna's appointment represents a full-time employment arrangement with the pharmaceutical company.

Professional Background

Mrs. Sandhya Amanna brings extensive legal expertise spanning over two decades across manufacturing, FMCG, and pharmaceutical sectors. Her comprehensive experience encompasses multiple leadership responsibilities in legal advisory, compliance, and governance functions.

As an in-house counsel, she has demonstrated expertise in:

• End-to-end contract management
• Dispute resolution and legal risk management
• Complex intellectual property litigation
• Compliance initiatives within pharmaceutical sector

Leadership Experience

In her previous role at Danone India, Mrs. Amanna served as Head of Legal, Compliance and Secretarial, where she drove the legal, compliance, and governance agenda for the organization. She collaborated closely with cross-functional leadership teams to manage legal risk, strengthen compliance frameworks, and support strategic business decisions.

Educational Qualifications

Mrs. Amanna holds an LLB degree from University of Mumbai and is an alumna of Government Law College, Mumbai. Her educational background provides a strong foundation for her legal expertise in the corporate sector.

Regulatory Compliance

The appointment disclosure was made pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has provided comprehensive details as required under SEBI Circular No. HO/49/14/14(7)2025 - CFD-POD2/I/3762/2026 dated January 30, 2026.

AstraZeneca Pharma India Limited has announced a postal ballot seeking shareholder approval for material related party transactions worth ₹3,900 crore for the financial year 2026-27. The company issued the postal ballot notice on February 11, 2026, with the cut-off date for determining eligible shareholders set as February 20, 2026.

Proposed Related Party Transactions

The pharmaceutical company seeks approval for two significant related party transactions through ordinary resolutions:

Transaction with AstraZeneca UK Limited

The first resolution proposes transactions worth ₹2,400 crore with AstraZeneca UK Limited, the parent company in the corporate structure. This amount represents 140% of the company's annual turnover for the financial year 2024-25. The transactions will cover purchase, transfer, or receipt of products, goods, materials, services, reimbursement and recovery costs, and transfer pricing obligations.

Transaction with AstraZeneca AB, Sweden

The second resolution seeks approval for transactions valued at ₹1,500 crore with AstraZeneca AB, Sweden, representing 87% of the annual turnover for financial year 2024-25. Similar to the UK entity, these transactions encompass the same range of business activities including product purchases, material transfers, and service arrangements.

E-Voting Schedule and Process

The company has established a comprehensive timeline for the postal ballot process:

Shareholders whose names appear in the Register of Members or List of Beneficial Owners as of the cut-off date will be eligible to participate in the e-voting process. The company has engaged National Securities Depository Limited (NSDL) to facilitate secure electronic voting.

Corporate Governance and Compliance

The proposed transactions align with the company's ordinary course of business in manufacturing and marketing pharmaceutical products. Both transactions have been reviewed and approved by the Audit Committee, which confirmed that the arrangements are conducted on an arm's length basis without any special benefits or privileges extended to the related parties.

Mr. Vijayakrishna K.T, a practicing Company Secretary from Bengaluru, has been appointed as the Scrutinizer to conduct the postal ballot process in a fair and transparent manner. The Scrutinizer will submit the final report to the Chairperson by March 31, 2026.

Business Rationale

The company stated that these transactions are essential for carrying out business operations and maximizing growth and performance. The arrangements are designed to meet growing business demands, accommodate changing product mix, and improve accessibility to patients. The aggregate value of these transactions exceeds 10% of the company's turnover, making them material in nature under SEBI regulations.

Results of the e-voting and the Scrutinizer's report will be made available on the company's website, NSDL's platform, and communicated to the National Stock Exchange of India Limited and BSE Limited where the company's equity shares are listed.